The 20 Best WT1-Related Wilms Tumor Syndromes Doctors Near Me in Teaneck, NJ

Michael Stifelman is a Urologist in Hackensack, New Jersey. Dr. Stifelman is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), UPJ Obstruction, Retroperitoneal Fibrosis, Nephrectomy, and Ureteral Reconstruction.

Robert Alter is an Otolaryngologist in Hackensack, New Jersey. Dr. Alter is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Urothelial Cancer, Endoscopy, and Nephrectomy.

Mutahar Ahmed is a Urologist in Maywood, New Jersey. Dr. Ahmed is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Bladder Cancer, Ureterocele, Nephrectomy, and Ureteral Reconstruction.

Gregory Lovallo is an Oncologist in Maywood, New Jersey. Dr. Lovallo is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Obstructive Uropathy, Muscle Invasive Bladder Cancer, Enlarged Prostate (BPH), Nephrectomy, and Reconstructive Urology Surgery.

James McKiernan, MD, is the John K. Lattimer Professor of Urology and CEO of ColumbiaDoctors. He is also Senior Vice Dean for Clinical Affairs for Columbia University Vagelos College of Physicians and Surgeons. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at NewYork-Presbyterian Hospital, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan's clinical practice is focused on urologic oncology and particularly on surgical therapy in high-risk patients with bladder and kidney cancers. Dr. McKiernan evaluates and treats over 1,000 patients with bladder cancer every year. His research, funded by NIH and biotechnology industry grants, focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In the management of kidney and bladder cancer, he has special expertise in organ preservation and reconstructive surgery to maximize quality of life. Dr. McKiernan's research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 220 scientific articles and book chapters on urologic cancer and related issues.For the past 10 years, he has directed a research team at Columbia University Medical Center investigating quality outcomes and effectiveness in urologic cancer surgery. He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Co-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia University/NYPH, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia's Herbert Irving Comprehensive Cancer Center, his team continues to develop new therapeutic strategies for managing bladder cancer. Dr. Mckiernan is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Cystectomy, and Nephrectomy.

Dr. Stein is an Associate Professor of Medical Oncology at Columbia University Medical Center. He is a recognized expert in field of genitourinary oncology – treating patients with prostate, kidney, bladder and testicular cancers. He is also a member of the Experimental Therapeutics program, investigating novel therapies across all solid tumors. In addition to providing standard therapies for the treatment of genitourinary cancers such as hormonal therapy, molecularly targeted therapy and chemotherapy, Dr. Stein leads multiple investigator initiated and industry sponsored clinical trials. Dr. Stein has a particular interest in the development of novel immune therapies for the treatment of prostate cancer, both in men with early recurrence of prostate cancer as well as in men with more advanced prostate cancer. He is also helping to lead two national trials in kidney cancer sponsored by the National Cancer Institute.Dr. Stein received his B.S. in Molecular Biophysics and Biochemistry from Yale University. He earned his medical degree at New York Medical College, receiving the graduation award in oncology for his published research. He completed a residency in internal medicine at Montefiore Medical Center, and a fellowship in Hematology and Medical Oncology at Mount Sinai Medical Center. Prior to joining Columbia University, Dr. Stein practiced genitourinary oncology for 13 years at Rutgers University and has been an author on over 60 publications including guidelines for assessing the efficacy of new drugs in prostate cancer and recommendations for the use of immunotherapy to treat prostate cancer. Dr. Stein is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), and Familial Prostate Cancer.

Benjamin A. Gartrell, MD, is Director, Genitourinary Malignancy Program at Montefiore and an Assistant Professor of Oncology and Urology at our Albert Einstein College of Medicine. Since joining the Montefiore team in 2012, his expertise has been in treating genitourinary malignancies including prostate cancer, bladder cancer, renal cell cancer, and testicular cancer. He is also very active in translating science findings in collaboration with research colleagues at Einstein. In 2000, Dr. Gartrell received his Bachelor of Arts in Chemistry at the College of Wooster in Ohio. Following this, he attended the Northwestern University?s Feinberg School of Medicine, in Chicago, Illinois, where he received his Doctor of Medicine in 2005. His postgraduate training began in 2005 with an internship and residency in Internal Medicine at Case Western Reserve University, which he completed in 2008. He then completed a fellowship in Hematology/Oncology at Mount Sinai School of Medicine in 2012 and became Chief Fellow from 2010-2011. With a vast range of research interests, Dr. Gartrell focuses on translational research evaluating the significance of a novel immune checkpoint molecule in bladder cancer, evaluating the role of the autonomic nervous system in?prostate cancer, toxicities associated with anticancer therapies, and the impact of bone metastasis on patients with prostate cancer. His work has been published in a number of peer-reviewed journals, including the Journal of Clinical Oncology, Urologic Oncology, and European Urology. Dr. Gartrell also participates in community outreach to promote Prostate Cancer Awareness. Dr. Gartrell is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Clear Cell Sarcoma, Nephrectomy, and Prostatectomy.

Robert Tassan is a Hematologist in Hackensack, New Jersey. Dr. Tassan is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Thrombocytopenia, Adult Immune Thrombocytopenia, Hemangioma Thrombocytopenia Syndrome, and Myelodysplastic Syndrome (MDS).

Ravi Munver is a Urologist in Hackensack, New Jersey. Dr. Munver is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Horseshoe Kidney, Prostate Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Thomas Christiano is a Urologist in Maywood, New Jersey. Dr. Christiano is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Horseshoe Kidney, Muscle Invasive Bladder Cancer, Enlarged Prostate (BPH), Ureteroscopy, and Reconstructive Urology Surgery.

Dr. Hiram Shaish graduated from Dartmouth College and received his M.D. from Mount Sinai School of Medicine. He is currently Assistant Professor of Radiology at Columbia University Medical Center (CUMC). Dr. Shaish completed his residency at Westchester Medical Center in Diagnostic Radiology and fellowship at New York University. He is a member of the Society of Abdominal Radiology. Dr. Shaish's research interests include Prostate MR imaging and cystic renal lesions. Dr. Shaish is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Pleurisy, Pleural Effusion, Muscle Invasive Bladder Cancer, Nasal Flaring, and Ureteroscopy.

Christine Cumarasamy is a Urologist in Saddle Brook, New Jersey. Dr. Cumarasamy is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Acute Cystitis, Ureteroscopy, and Nephrectomy.

Joshua Chaim is a Radiologist in New York, New York. Dr. Chaim is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Ureterocele, and Prostatectomy.

Anita Price is a Pediatric Radiologist in New York, New York. Dr. Price is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Pleurisy, Pleural Effusion, WT1-Related Wilms Tumor Syndromes, Pancreaticoduodenectomy, and Orchiectomy.

James Fuqua is a Radiologist in New York, New York. Dr. Fuqua is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Muscle Invasive Bladder Cancer, ALK-Positive Non-Small Cell Lung Cancer, and Lymphoid Hyperplasia.

Debra Sarasohn is a Radiologist in New York, New York. Dr. Sarasohn is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are WT1-Related Wilms Tumor Syndromes, Renal Cell Carcinoma (RCC), Ascites, and Thyroid Nodule.

Omer Aras is a Radiologist in New York, New York. Dr. Aras is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Renal Cell Carcinoma (RCC), and Liver Embolization.

Oguz Akin is a Radiologist in New York, New York. Dr. Akin is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Prostatectomy.

Jonathan Landa is a Radiologist in New York, New York. Dr. Landa is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Liposarcoma, Ganglioneuroblastoma, Rhabdoid Tumor Predisposition Syndrome, and Synovial Sarcoma.

James Park is a Radiologist in Teaneck, New Jersey. Dr. Park is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Pleurisy, Pleural Effusion, Gallbladder Disease, and Angiomyoma.